Lars Østergaard, MD, PhD, of the clinical medicine and infectious diseases departments of Aarhus University Hospital in Denmark, and colleagues reported in The New England Journal of Medicine  trial studies on Trumenba, a bivalent meningococcal B vaccine.

Meningococcal B accounts for a large proportion of invasive meningococcal disease among individuals aged 10 to 25 years in the United States, Europe and other regions.

They concluded that Trumenba is safe and immunogenic in adolescents and young adults after two and three doses, according to the results of two phase 3 trials.

Read the full story here